Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment

AIDS

Volumn 27, Issue 17, 2013, Pages 2759-2763

  Girard, Pierre Marie ^a   Nelson, Mark ^b   Mohammed, Perry ^c   Hill, Andrew ^d   Van Delft, Yvon ^e   Moecklinghoff, Christiane ^f  

^a HÔPITAL SAINT ANTOINE   (France)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c Janssen Global Access and Partnership Program   (United Kingdom)

^d Oncology R and D   (United Kingdom)

^e Janssen EMEA   (Netherlands)

^f Janssen EMEA   (Germany)

Author keywords

CD4+ cell count; Darunavir; Diagnostics; HIV RNA; Monitoring; Ritonavir

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIRETROVIRAL TREATMENT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; FOLLOW UP; GENE REPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; RNA, VIRAL; VIRAL LOAD;

EID: 84888305678     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432458.98851.c1     Document Type: Article

References (11)

1. Holkmann Olsen C, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. Risk of AIDS and death at given HIV-RNA and CD4R cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330.
2. Zoufaly A, an der Heiden M, Kollan C, Bogner J, Faetkenheuer G, Wasmuth J, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 2010; 203:364-371.
3. Gale H, Gitterman S, Hoffman H, Gordin F, Benator D, Kan V. Is frequent CD4R T-lymphocyte monitoring necessary for persons with counts >U300 cells/uL and HIV-1 viral suppression. Clin Infect Dis 2013advanced access publication.
4. Phillips A, Youle M, Lampe F, Sabin C, Hill A, Ransom D, et al. CD4R cell count changes in individuals with counts above 500 cells/mm3 and viral loads below 50 copies/ml on antiretroviral therapy. AIDS 2002; 16:1073-1075.
5. Stephan C, Hill A, Xi N, van Delft Y, Moecklinghoff C. Is monitoring for CD4R counts still needed for the management of patients with long-term HIV RNA suppression. J Acquir Immune Defic Syndr 2012; 61e73-e75.
6. Gazzard B, Moecklinghoff C. Hill A. new strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinico Econ Outc Res 2012; 4:193-200.
7. Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatmentna ve HIV-1-infected patients at week AIDS 2008:1389-1397.
8. Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lauthowers E, et al. Final 192 week efficacy and safety of oncedaily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1 infected treatment-nave patients in the ARTEMIS trial. HIV Med 2013; 14:49-59.
9. Van Sighem A, Zhang S, Reiss P, Gras L, van der Ende M, Kroon F, et al. Immunologic, virologic and clinical consequences of episodes of transient viraemia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:104-108.
10. Garcia-Gasco P, Maida I, Blanco F, Barriero P, Martin-Carbonera L, Vispo E, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61: 699-704.
11. Yang Y, Beamon J, Seiss K, Lichterfield M, Rosenberg E, Pereyra F, et al. Peripheral mechanisms of CD4 T cell regeneration in HIV-1 elite controllers. 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, USA, 20-23 October 2011 [abstr 841].